Cargando…

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer

OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and B...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Wenhui, Ma, Hongshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913982/
https://www.ncbi.nlm.nih.gov/pubmed/27366083
http://dx.doi.org/10.2147/OTT.S101319
_version_ 1782438491361116160
author Song, Wenhui
Ma, Hongshun
author_facet Song, Wenhui
Ma, Hongshun
author_sort Song, Wenhui
collection PubMed
description OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated. RESULTS: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044). CONCLUSION: The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy.
format Online
Article
Text
id pubmed-4913982
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49139822016-06-30 The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer Song, Wenhui Ma, Hongshun Onco Targets Ther Original Research OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated. RESULTS: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044). CONCLUSION: The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy. Dove Medical Press 2016-06-15 /pmc/articles/PMC4913982/ /pubmed/27366083 http://dx.doi.org/10.2147/OTT.S101319 Text en © 2016 Song and Ma. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Song, Wenhui
Ma, Hongshun
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title_full The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title_fullStr The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title_full_unstemmed The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title_short The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
title_sort expression of ercc1 and brca1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913982/
https://www.ncbi.nlm.nih.gov/pubmed/27366083
http://dx.doi.org/10.2147/OTT.S101319
work_keys_str_mv AT songwenhui theexpressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer
AT mahongshun theexpressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer
AT songwenhui expressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer
AT mahongshun expressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer